Navigation Links
Cephalon Announces FDA Approval of Risk Evaluation and Mitigation Strategies for NUVIGIL and PROVIGIL
Date:10/22/2010

icated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work disorder (SWD), or narcolepsy.  In patients with OSA, NUVIGIL is used along with other medical treatments for this condition.  The NUVIGIL (armodafinil) label includes a bolded warning for serious or life-threatening rash, including Stevens-Johnson Syndrome, requiring hospitalization and discontinuation of treatment, that has been reported in adults in association with the use of modafinil and armodafinil and in children in association with the use of modafinil, a racemic mixture of S and R modafinil (the latter is armodafinil, the active ingredient in NUVIGIL).  NUVIGIL is not approved for use in pediatric patients for any indication. The most common adverse events in controlled clinical trials (five percent or greater) were headache, nausea, dizziness, and insomnia.  Full prescribing information for NUVIGIL is available at www.nuvigil.com.

About PROVIGIL PROVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with treated obstructive sleep apnea (OSA), shift work sleep disorder, also known as shift work disorder (SWD), and narcolepsy.  In patients with OSA, PROVIGIL is used along with other medical treatments for this condition.  The PROVIGIL label includes a bolded warning for serious or life-threatening rash, including Stevens-Johnson Syndrome, requiring hospitalization and discontinuation of treatment, that has been reported in adults and children taking modafinil.  PROVIGIL is not approved for use in pediatric patients for any indication.

The most common adverse events in controlled clinical trials (greater than five percent) were headache, nausea, nervousness, rhinitis, diarrhea, back pain, anxiety, insomnia, dizziness and dyspepsia.  Full prescribing information for PROVIGIL is availabl
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
3. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
4. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
9. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
10. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
11. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)...  Celsion Corporation (NASDAQ: CLSN ), an oncology ... Tardugno , Chairman, President and CEO, is scheduled to ... Wednesday, July 8, 2015, at 4:15 p.m. Eastern Time. The ... located at 119 W. 56th Street, New ... of the presentation will be available in the Events ...
(Date:7/1/2015)... 2015 Radiant Insights announce that ... Concentrators Market Shares, Strategy, and Forecasts, Worldwide, 2015 ... growth as the aging population worldwide needs homecare oxygen ... where oxygen is able to improve the quality of ... become affordable and support a mobile lifestyle even while ...
(Date:7/1/2015)... July 1, 2015 New exchange plan enrollees ... 2015 compared to the same time a year ago, ... (NASDAQ: ESRX ) Exchange Pulse™ report, released today. ... 2014, the number of new exchange plan enrollees who ... in the first quarter of 2015. However, when evaluating ...
Breaking Medicine Technology:Celsion Corporation to Present at Cantor Fitzgerald's Inaugural Healthcare Conference on July 8, 2015 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 2Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 3Stationary Oxygen Concentrators Market to Reach $2 Billion by 2021: Radiant Insights, Inc. 4Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 2Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 3Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 4Express Scripts Provides First Look at 2015 Public Exchange Pharmacy Trends 5
... 30 London Genetics Limited, an expert in,the ... development, has,entered an intensive partnering programme following on ... recognised that while,pharmacogenetics and genetics have great potential ... early clinical,collaboration between companies, academia, regulators and payers ...
... FRANCISCO, Oct. 30 CCBR-SYNARC, the world,s leading provider ... center services to the pharmaceutical and biotechnology industries, announced ... for use in imaging clinical trials. , SYNARC has ... 2004. With the release of the enhanced SynarcConnect(SM) ...
Cached Medicine Technology:London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference 2London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference 3London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference 4CCBR-SYNARC Expands Electronic Data Capture Capabilities 2
(Date:7/1/2015)... ... 01, 2015 , ... Ormco Corporation, a leading manufacturer and ... Smile for a Lifetime Foundation (S4L) fundraising event held at the 14th Annual ... S4L in its mission to provide free quality orthodontic care to individuals with ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... a new extraction plant for Linablue®, Spirulina-derived natural blue food coloring. Construction of ... the DIC Group’s U.S. Spirulina* production base, began in May 2014. After commissioning, ...
(Date:7/1/2015)... ... , ... The Collaborative for Children and Families (CCF) announced that it received ... CCF to improve quality of care and save costs for the child welfare sector ... changes in New York’s Medicaid system. Experts agree that children need thorough solutions to ...
(Date:7/1/2015)... ... July 01, 2015 , ... OncLive® will team ... America (HCA), as it further expands its Strategic Alliance Partnership Program for raising ... new partnership, OncLive’s editorial and marketing teams will collaborate with Sarah Cannon to ...
(Date:7/1/2015)... Doylestown, PA (PRWEB) , ... July 01, 2015 ... ... Services national sales training leaders Lora Posey (Manager, National Sales Training and Development) ... Trainers and Educators Network (LTEN) Conference in Phoenix, AZ. LTEN brings together learning ...
Breaking Medicine News(10 mins):Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 2Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 3Health News:Mission Pharmacal Company: Alamo Pharma Services' Training Leaders Take Steps to Further Expand Capabilities for Mission Pharmacal and Other Clients 4
... Conference Foundation Prize in Pediatric, Oncology for Novel Approaches for ... ... SUNNYVALE, Calif., April 3, 2008 Xoft consulting,medical director, Mark ... Oncology for his research focused on novel,approaches for using KV X-ray-based ...
... Kelly Ripa Team Up to Promote New Appliance Line,s European, Style ... ... -, NEW YORK, April 3, 2008 Known and admired for ... is tapping Kelly Ripa for the North America launch of its new,premium ...
... within primary breast tumors can empower cells that break ... organs, researchers report in the April 4th Cell, a ... hundreds of human breast tumors, the researchers found evidence ... breast cancer cells for metastasis to the lungs, one ...
... Prenatal syphilis screening, recommended by the Centers ... health authorities, is critical to preventing still births ... mothers. A study published in the April ... that state Medicaid statistics, when used to determine ...
... Selective,Insurance Group, Inc. announced the following ... America ("Selective"):, Yanina Hupka (Sparrowbush, NY), ... she served as assistant vice president,and assistant ... 2000 as a,senior reinsurance accountant. Before coming ...
... and unstated feelings about Clinton, BOSTON, April 3, ... "insecure" than they are typically willing,to admit, according to ... "confidence" voters express about the U.S. Senator from New,York ... does not appear to be,very deep., Emotion Mining, ...
Cached Medicine News:Health News:Xoft Medical Director Recognized by Gotham Prize for Cancer Research 2Health News:Xoft Medical Director Recognized by Gotham Prize for Cancer Research 3Health News:Europe's Leading Premium Appliance Brand Taps America's Most Stylish, Multi-Tasking Mom to Launch New Appliance Line in North America 2Health News:Europe's Leading Premium Appliance Brand Taps America's Most Stylish, Multi-Tasking Mom to Launch New Appliance Line in North America 3Health News:Europe's Leading Premium Appliance Brand Taps America's Most Stylish, Multi-Tasking Mom to Launch New Appliance Line in North America 4Health News:Human breast tumors' 'microenvironment' primes them for metastasis 2Health News:Prenatal syphilis screening rates: Are they being accurately reported? 2Health News:Voting for Clinton Evokes Deep-Seated Feelings of Insecurity 2
Fixed smooth rod which slides on skin. Designated most popular model or size....
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
6 mm x 23 mm blunt, double-edged blade. Flat handle....
Double-ended. Blades set at 45 and 90 degrees. Hexagonal handle....
Medicine Products: